Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
339.7 USD | +0.04% | -0.75% | -5.99% |
Apr. 30 | TD Cowen Adjusts Price Target on Molina Healthcare to $412 From $453, Keeps Buy Rating | MT |
Apr. 29 | Wells Fargo Adjusts Price Target on Molina Healthcare to $375 From $410 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.42 for the 2024 fiscal year.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.99% | 19.91B | B- | ||
-6.46% | 453B | B- | ||
+11.75% | 122B | A- | ||
+14.04% | 96.87B | B- | ||
+0.81% | 39.92B | B- | ||
-29.98% | 38.63B | A- | ||
-14.69% | 3.05B | C+ | ||
-23.00% | 1.26B | B- | ||
-27.00% | 345M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOH Stock
- Ratings Molina Healthcare, Inc.